How to Stack SS-31 + MOTS-C (Exact Dosing Protocol)

Your mitochondria are doing two different jobs at the same time, and most people trying to support them are only addressing one.

To understand why stacking SS-31 and MOTS-c makes sense, you need the full picture of what mitochondria actually do and where each of these compounds fits in that picture.

The mitochondrion is not just an energy generator. It has a physical structure, an inner membrane folded into tight ridges called cristae, and it has a signaling function, sending molecular messages out to the rest of the cell that regulate metabolism, inflammation, and gene expression. When mitochondria age or get damaged, both of those things break down. The structure deteriorates and the signaling gets noisy. SS-31 and MOTS-c each target one of those two problems, which is exactly why combining them is a coherent idea rather than just stacking peptides for the sake of it.

Start with SS-31, because its mechanism is more structural than most people realize.

Inside the inner mitochondrial membrane, there is a molecule called cardiolipin, which is a specialized fat that acts as a kind of anchor and organizer for the proteins that generate ATP. When cardiolipin gets oxidized or displaced, the entire electron transport chain starts to fall apart. The proteins that are supposed to sit next to each other separate, electrons leak, and instead of producing ATP cleanly, the mitochondrion starts spitting out something called reactive oxygen species, which are unstable molecules that damage everything around them.

SS-31 binds directly to cardiolipin. Not to a receptor, not to a protein, but to the fat molecule itself. Because of its electrical charge, it concentrates at that inner membrane at roughly 5,000 times the concentration found in surrounding tissue, so even small doses arrive at the target in meaningful amounts. By stabilizing cardiolipin, SS-31 allows the electron transport chain to reassemble into its proper configuration, which reduces the electron leak, which reduces the reactive oxygen species, which allows ATP production to recover.

This is a structural repair happening over weeks of consistent exposure, not an acute effect. SS-31 has a half-life of about two hours, so it clears the blood quickly, but the benefit it produces is cumulative because you are progressively restoring the architecture of a membrane, not temporarily blocking a receptor.

The dosing data on SS-31 in humans is cleaner than most people expect. A trial comparing 4 milligrams per day against 40 milligrams per day found that the higher dose produced no additional benefit. That makes sense once you understand the concentration mechanism. The membrane reaches saturation at relatively low circulating levels. Going higher does not help because the binding sites are already occupied. The practical range for most people is 1 to 5 milligrams daily, and one of the longest running human trials, 168 weeks of continuous daily dosing at 40 milligrams, showed progressive improvement across the full window with no evidence of tolerance developing.

That last point matters because it is the strongest argument against cycling SS-31. Tolerance requires receptor downregulation, and there is no receptor here. The cardiolipin binding site does not get desensitized. The 168-week trial is the longest continuous human data set available for any compound in this class, and it showed no plateau and no adverse signal.

Now shift to MOTS-c, because the mechanism is completely different.

MOTS-c is something called a mitochondrial-derived peptide, which means it is actually encoded in the mitochondrial genome and produced inside your own mitochondria under normal conditions. Exercise increases it. Aging decreases it. When MOTS-c is released from the mitochondrion, it travels to the nucleus and activates a transcription program, meaning it changes which genes are being read, not just which proteins are being activated in the moment.

The primary pathway runs through something called AMPK, which is a cellular energy sensor that acts like a thermostat. When AMPK is activated by MOTS-c, it triggers a downstream cascade that improves how mitochondria process fuel, reduces oxidative stress, and preserves muscle function during aging. A 2021 study found that older mice treated with MOTS-c three times per week maintained the physical capacity of much younger animals, and that this held even when dosing was dropped from daily to three times per week after an initial loading period.

The reason three times per week works is that MOTS-c operates through gene expression changes that persist long after the peptide itself has cleared. The signal lasts. You do not need the peptide in circulation continuously because you are not blocking a pathway that will reactivate the moment the compound is gone. You are instructing the cell to behave differently, and the cell keeps following those instructions for days.

There is also a quality component here beyond just output. A more recent study found that MOTS-c improves mitochondrial efficiency, specifically the ratio of ATP produced per unit of oxygen consumed, without increasing the total number of mitochondria. That is a meaningful distinction. It is not just more, it is better, and it reduces the reactive oxygen species that SS-31 is also working to reduce from the structural side.

Which is the whole point of combining them. SS-31 is stabilizing the physical structure so the electron transport chain can run cleanly. MOTS-c is activating the gene program that optimizes how the cell fuels and manages that machinery. They reach the same destination through different roads, and there is no known mechanism by which one would interfere with the other.

The protocol the data most supports looks like this: SS-31 at 1 to 5 milligrams daily, because the short half-life and cumulative structural benefit require consistent exposure. MOTS-c at 5 to 15 milligrams per week split across Monday, Wednesday, and Friday. A reasonable starting point is 2 milligrams SS-31 daily and 10 milligrams MOTS-c per week, with lower starting doses for those new to peptides and higher doses for significant age-related decline.

The standard recommendation is to cycle both compounds with 8 to 12 weeks on and 4 to 8 weeks off. That recommendation is precautionary, not mechanistic. Neither compound has a known desensitization pathway, and the human data available does not show any signal that would require time off. The cycling guidance exists because long-term human data at these specific doses does not yet exist, and that is the honest reason to include an off period, not because there is evidence of harm, but because the absence of evidence is not the same as evidence of safety.

One more thing worth being clear about: no human study has tested these two compounds together. The combination logic is built from how each one works individually and the observation that their mechanisms target genuinely separate problems. That is where the evidence stands right now.

Most age-related mitochondrial decline is not one problem. It is structure failing and signaling failing at the same time. Fixing only one of them is like replacing the engine in a car while leaving the fuel system clogged. You will get some improvement. You will not get the full picture.

---

References

1. Thompson WR, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a mitochondrial cardiomyopathy. Genetics in Medicine. 2024;267:101133. 168-week continuous SS-31 at 40mg daily with progressive improvement and no tolerance. Source
2. Butler J, et al. Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: The PROGRESS-HF phase 2 trial. Journal of Cardiac Failure. 2020;265:429-437. 4mg vs 40mg comparison: 40mg showed no advantage over 4mg. Source
3. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470. 3x/week maintenance dosing preserved all benefits after daily loading. Source
4. Gudiksen A, et al. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1alpha/AMPK-dependent manner. Free Radical Biology and Medicine. 2026;246:682-696. MOTS-C improves mitochondrial quality without increasing content, reduces ROS. Source
5. Whitson JA, et al. SS-31 and NMN: Two paths to improve metabolism and function in aged hearts. Aging Cell. 2020;1910:e13213. Closest published combination data: SS-31 + NMN synergy in aged mice. Source
6. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;213:443-454. Original MOTS-C dosing data: 0.5mg/kg chronic, 5mg/kg acute in mice. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness